Paul J. Brindley

The paper identifies fluke-borne viruses as risk factors and diagnostic targets for cancers caused by carcinogenic trematodes.

The paper demonstrates that CRISPR/Cas12a with modified transgenes achieves more efficient gene knock-in in Schistosoma mansoni compared to Cas9.

The paper identifies and characterizes genomic safe harbor sites in Schistosoma mansoni to enable consistent transgene activity through CRISPR/Cas-assisted homology-directed repair.

This paper identifies and characterizes SmNAGAL, a glycosyl hydrolase in Schistosoma mansoni, showing its role in coordinating parasite movement and egg production, suggesting it as a potential target for new anthelmintic drugs.

This study compares the efficiency of Cas12a and Cas9 for gene knockout and knock-in in Schistosoma mansoni, finding AsCas12a more efficient for knockout but SpCas9 more precise for knock-in.

The paper investigates how PIWI and retrotransposon nimbus interact to modulate resistance to Schistosoma mansoni in Biomphalaria glabrata snails through epigenetic mechanisms.

This study analyzes the transcriptome of Schistosoma mansoni developing eggs to identify genes involved in pathogenesis and life cycle progression.

This paper uses CRISPR/Cas9 to edit the acetylcholinesterase gene in Schistosoma mansoni eggs, resulting in reduced AChE activity and decreased granuloma size in mice.

The paper shows that CagA+ Helicobacter pylori infection induces epithelial to mesenchymal transition in human cholangiocytes, promoting migration, invasion, and colony formation.

This paper uses CRISPR/Cas9 to knockout the BgAIF gene in Bge cells, showing reduced adherence to Schistosoma mansoni sporocysts.

The paper investigates how liver fluke granulin promotes exosome-mediated crosstalk that alters the cellular microenvironment to support cholangiocarcinoma development.

This paper demonstrates CRISPR/Cas9-based genome editing in Schistosoma mansoni, successfully mutating the omega-1 gene and reducing Th2 cytokine responses and granuloma formation.

This study uses CRISPR/Cas9 to knockout the Ov-grn-1 gene in liver flukes, showing reduced biliary tract pathology in infected hamsters.